Resistance to lysosomotropic drugs used to treat kidney and breast cancers involves autophagy and inflammation and converges in inducing CXCL5

Lysosomotropic agents such as sunitinib, lapatinib, and chloroquine belong to a drug family that is being used more frequently to treat advanced cancers. Sunitinib is standard care for metastatic renal cell carcinomas (mRCC) and lapatinib is used for trastuzumab/pertuzumab-refractory cancers. Howeve...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Theranostics
Glavni autori: Giuliano, Sandy, Dufies, Maeva, Ndiaye, Papa Diogop, Viotti, Julien, Borchiellini, Delphine, Parola, Julien, Vial, Valérie, Cormerais, Yann, Ohanna, Mickaël, Imbert, Véronique, Chamorey, Emmanuel, Rioux-Leclercq, Nathalie, Savina, Ariel, Ferrero, Jean-Marc, Mograbi, Baharia, Pagès, Gilles
Format: Artigo
Jezik:Inglês
Izdano: Ivyspring International Publisher 2019
Teme:
Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6401402/
https://ncbi.nlm.nih.gov/pubmed/30867824
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/thno.29093
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items